DREAMM-10
A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Near Add Your Location
Sorting 29 by
Virginia Cancer Specialists
Fairfax, VA
- Accepting patients
Florida Cancer Specialists - North - The Villages
Lady Lake, FL
- Accepting patients
- Accepting patients
University of Massachusetts Medical School
Worcester, MA
- Accepting patients
Texas Oncology
Tyler, TX
- Accepting patients
Lifespan Rhode Island Hospital
Providence, RI
- Accepting patients
University of Texas at Austin
Austin, TX
- Accepting patients
Rocky Mountain Cancer Centers
Aurora, CO
- Accepting patients
The Oncology Institute of Hope and Innovation
Pasadena, CA
- Accepting patients
Ohio State University Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute
Columbus, OH
- Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.